Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IASO104 in Relapsed/Refractory Multiple Myeloma
NCT07185490Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2026
- Primary completion
- Aug 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of IASO104 in multiple myeloma (MM) and plasma cell leukemia (PCL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Incidence and severity of adverse events at 2 years. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
IASO104
03
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT07185490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07185490.